2003 Quarterly Earnings Reports
Pharmaceutical Sector Companies
Updated 11/01/04
Current publicly reported financial results (in $millions) for pharmaceutical-based companies. Please note that all figures may reflect non-recurring charges, credits, gains or losses. Company fiscal years may not run according to the calendar year. Earnings will be updated as Network Science receives the data.
| Q1 | Q2 | Q3 | Q4 | YTD | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Income | Revenue | Income | Revenue | Income | Revenue | Income | Revenue | Income | |
| Abbott (ABT) | $4,580.5 | $801.0 | $4,126.3 | $246.6 | $4,247.9 | $761.2 | $5,530.6 | $944.4 | $18,485.3 | $2,753.2 |
| Wyeth (WYE) | $3,689.1 | $1,277.9 | $3,746.6 | $864.4 | $4,081.6 | ($426.4) | $4,333.4 | $335.3 | $15,850.7 | $2,051.2 |
| AstraZeneca | $4,735.0 | $932.0 | $4,436.0 | $666.0 | $4,803.0 | $803.0 | $4,875.0 | $635.0 | $18,849.0 | $3,036.0 |
| Aventis (In Euros) | 4,254.0 | 201.0 | 4,480.0 | 612.0 | 4,259.0 | 640.0 | 4,391.0 | 716.0 | 17,384.0 | 2,169.0 |
| Bayer (in Euros) | 7,356.0 | 586.0 | 7,256.0 | 458.0 | 6,834.0 | (123.0) | 7,121.0 | (1,952.0) | 28,567.0 | (1,031.0) |
| Bristol-Myers Squibb (BMS) | $4,728.0 | $792.0 | $5,129.0 | $902.0 | $5,372.0 | $906.0 | $5,571.0 | $429.0 | $20,671.0 | $2,952.0 |
| Eli Lilly (LLY) | $2,889.4 | $407.0 | $3,088.2 | $692.2 | $3,139.4 | $714.4 | $3,465.5 | $747.2 | $12,582.5 | $2,560.8 |
| GlaxoSmithKline | $8,355.0 | $1,911.0 | $8,706.0 | $2,153.0 | $8,800.0 | $1,883.0 | $9,302.0 | $1,407.0 | $35,163.0 | $7,354.0 |
| Hoffmann-La Roche (in CHF) | 15,188.00 | 1,289.00 | 15,893.00 | 1,780.00 | 31,081.00 | 3,069.00 | ||||
| Valeant Pharmaceuticals (VRX) | $158.7 | $13.7 | $183.5 | $14.9 | $167.5 | ($82.4) | $176.2 | ($1.8) | $685.9 | ($55.6) |
| Johnson & Johnson (JNJ) | $9,822.0 | $2,071.0 | $10,332.0 | $1,210.0 | $10,455.0 | $2,072.0 | $11,254.0 | $1,845.0 | $41,863.0 | $7,198.0 |
| Merck (MRK) | $5,571.4 | $1,710.4 | $5,525.4 | $1,867.0 | $5,762.0 | $1,858.3 | $5,627.1 | $1,395.2 | $22,485.9 | $6,830.9 |
| Novartis | $5,721.0 | $1,063.0 | $6,203.0 | $1,316.0 | $6,210.0 | $1,277.0 | $6,730.0 | $1,360.0 | $24,864.0 | $5,016.0 |
| Pfizer (PFE) | $8,525.0 | $4,665.0 | $9,993.0 | ($3,591.0) | $12,348.0 | $2,235.0 | $14,167.0 | $602.0 | $45,033.0 | $3,911.0 |
| Pharmacia Corp | Purchased by Pfizer in Q2/2003 | |||||||||
| Schering-Plough (SGP) | $2,082.0 | $173.0 | $2,308.0 | $182.0 | $1,998.0 | ($265.0) | $1,948.0 | ($181.0) | $8,334.0 | ($92.0) |
| Totals for Results in USD | $60,857.1 | $15,817.0 | $63,776.9 | $6,523.1 | $67,384.4 | $11,736.1 | $72,979.8 | $9,517.3 | $264,867.2 | $43,515.5 |
